Stay connected! Share and follow:

Leukaemia CARE Careline

We're here to talk | 24-hours a day

08088 010 444

FREE from landlines & most major mobile networks

NICE decision on blinatumomab

written by

Leukaemia Care, Charity

  • PIXABAY-30032016-medications-257333_1920

The National Institute for Health and Care Excellence (NICE) has today issued its final appraisal determination (FAD) in relation to the appraisal of blinatumomab (ID 804). Blinatumomab is marketed by Amgen as Blincyto®.

NICE has recommended blinatumomab for treating:

As a result, it will soon be routinely available to patients in England. Blinatumomab is already available in Scotland and Wales, having been approved by the Scottish Medicines Consortium (SMC) in June 2016 and All Wales Medicines Strategy Group (AWMSG) in July 2016.

This decision will bring to an end regional variations which prevented English patients from accessing a treatment that was readily available to Scottish and Welsh patients.

Leukaemia CARE strongly believes that access to treatment should be consistent for all NHS patients in the UK, as highlighted in our Cancer Lottery campaign. We have been involved throughout NICE’s appraisal of blinatumomab and are delighted with the recommendation.

Zack Pemberton-Whiteley, Head of Campaigns and Advocacy at Leukaemia CARE commented:

“Living with ALL, particularly when first line treatment has failed, can have a profound impact on the person’s physical and psychological wellbeing. It can also place a big emotional strain on their families and friends.

Effective therapeutic options like blinatumomab could have an impact on the quality of life of people living with ALL. For patients, the knowledge that there are alternative treatments available can provide some relief.

We are pleased that NICE has recommended blinatumomab be made routinely available to patients in England and Wales. This is consistent with a previous decision from the Scottish Medicines Consortium, ending the variations in access between England and Scotland.”

For further information, please contact our Campaigns and Advocacy team. They are available Monday to Friday from 9:00am – 5:30pm. If you would like to contact them, you can:

For more information on acute lymphoblastic leukaemia (ALL), please click here.